INAB IN8bio, Inc.
USHealthcareAs of 2026-07-10 12:16
Why INAB matters now
IN8bio, Inc. (INAB) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.42 with +1.42% on the session and $13.6M in market capitalization; recent performance reads 1-month -1.38% and YTD -38.89%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-5.1M, and EPS of $-1.16. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -103.3%.
The latest indexable market news headline is "IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $4.00; recent insider activity includes FAIRBAIRN EMILY filing G-Gift. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.27
P/S
0.00
EV/EBITDA
0.33
DCF Value
$5.49
FCF Yield
-103.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-96.4%
ROA
-72.3%
ROIC
-76.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-5.1M | $-1.16 |
| Q4 2025 | $0.00 | $-4.9M | $-0.51 |
| FY 2025 | $0.00 | $-19.4M | $-4.44 |
| Q3 2025 | $0.00 | $-3.9M | $-0.85 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$4.00
Target (Median)
$4.00
Target Range
$4.00 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.19
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.